Senior Vice President Regulatory Affairs and Quality Assurance
Peter DiRoma joined Melinta Therapeutics as vice president regulatory affairs and quality assurance in June 2014, bringing with him 19 years of experience in the development, approval and launch of pharmaceuticals, including the global development and NDA registration of Zyvox® (linezolid) for multi-drug resistant pathogens.
Prior to joining Melinta, Mr. DiRoma served as vice president of global regulatory affairs at Dendreon Corporation, overseeing the European registration of PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castration- resistant prostate cancer. Earlier, Mr. DiRoma held regulatory leadership positions in large pharma including Merck KGaA/EMD Serono, where he was vice president regulatory affairs, providing regulatory guidance for the company’s immunology, oncology, and neurodegenerative disease development portfolio. Before joining Merck KGaA, he held regulatory positions at Pharmacia & Upjohn and Pfizer where he was an integral member of the team that led the Phase 3 and subsequent global regulatory programs for Zyvox®, a first-in-class antibiotic for Gram-positive infections, including those resistant to vancomycin.
Mr. DiRoma holds a B.S. in chemistry and biology from the University of South Florida. He received undergraduate research grants from the American Cancer Society at the University of South Florida College of Medicine and from the National Science Foundation in cancer immunology at the Florida State University Institute of Molecular Biophysics.